Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

NCT03424473 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03424473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03424473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Lead sponsor
Seagen Inc.
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported